EDIT compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

EDITEditas Medicine, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

EDITEditas Medicine, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only EDIT 11

VRTXVertex Pharmaceuticalscustomer

BMYBristol Myers Squibbcustomer

BEAMBeam Therapeuticscustomer

—The Broad Instituteunlistedsupplier

7 more · EDIT chain ›

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

EDITEditas Medicine, Inc.

2.65▼−9.48%· post 2.62

Mkt cap$410.1MRevenue$12MQ2 FY26Revenue—

AMGNAmgen Inc

466.31▲+1.21%· post 466.40

ClosedOct 30 '26

Mkt cap$251.9BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

Compare

ClosedOct 30 '26

EDITEditas Medicine, Inc.

AMGNAmgen Inc

2.65▼−9.48%post 2.62

Price

466.31▲+1.21%post 466.40

$410.1M

Mkt cap

$251.9B

Q2 FY26$12M

Revenue

$10.1BQ2 FY26

—

Revenue

$36.8BFY25

EDIT2.65▼−9.48%vsAMGN466.31▲+1.21%ClosedOct 30 '26